Form SC 13G Magenta Therapeutics, Filed by: GV 2016, L.P.
Magenta Therapeutics, Inc. (MGTA)
Last magenta therapeutics, inc. earnings: 11/13 08:00 am
Check Earnings Report
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
MGTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTA alerts
High impacting Magenta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MGTA
News
- Magenta Therapeutics, Inc. (NASDAQ: MGTA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $1.00 price target on the stock.MarketBeat
- Magenta Therapeutics, Inc. (NASDAQ: MGTA) is now covered by analysts at HC Wainwright. They set a "neutral" rating on the stock.MarketBeat
- Magenta Therapeutics up 47% on plan to pursue strategic alternatives [Seeking Alpha]Seeking Alpha
- Magenta Therapeutics to Explore Strategic AlternativesGlobeNewswire
- Magenta Therapeutics, Inc. (NASDAQ: MGTA) had its "neutral" rating re-affirmed by analysts at BTIG Research.MarketBeat
MGTA
Earnings
- 11/3/22 - Beat
MGTA
Sec Filings
- 3/23/23 - Form 10-K
- 2/14/23 - Form SC
- 2/14/23 - Form SC
- MGTA's page on the SEC website